Navigation Links
Omega Protein Reports 2008 Results
Date:3/10/2009

HOUSTON, March 10 /PRNewswire-FirstCall/ -- Omega Protein Corporation (NYSE: OME), the nation's leading producer of Omega-3 fish oil and specialty fish meal products, today reported net income of $12.6 million ($0.69 a share) for the fiscal year ended December 31, 2008, compared with net income of $12.1 million ($0.72 a share) for the year ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO)

For the year ended December 31, 2008, the Company had revenues of $177.4 million, compared with $157.1 million in revenues for the year ended December 31, 2007. Omega Protein recorded operating income of $23.5 million for the year ended December 31, 2008, versus operating income of $27.4 million for the comparable period a year earlier.

Revenues for the fourth quarter ended December 31, 2008 were $39.7 million compared with revenues of $44.3 million for the comparable quarter in 2007. Omega Protein recorded operating income of $2.5 million for the 2008 fourth quarter, versus operating income of $8.8 million for the fourth quarter of 2007.

The Company's 2008 results, in comparison to 2007, after excluding the effects of hurricane losses, insurance recoveries and debt refinancing costs from each of the reported periods, experienced growth in revenues (13%), gross profit (24%) and net income (80%). The 2008 results reflect increased pricing, particularly for fish oil, similar to other commodity markets during the first half of 2008, offset by decreased sales volumes. Commodity prices began to decrease mid year which contributed to declining gross profit margins in the third and fourth quarters of 2008.

During the quarter ended September 30, 2008, the Company suffered wind and flood damage to two facilities as a result of Hurricane Ike. The Company's Abbeville, Louisiana facility was restored to full capacity within a few weeks. The Company's Cameron, Louisiana facility is continuing its repairs and is expected to be fully functional for the beginning of the 2009 fishing season. Losses resulting from Hurricane Ike, net of insurance proceeds, were approximately $2.0 million. The Company's 2008 third and fourth quarter gross margins were further reduced primarily due to significantly higher per unit production costs due to the lost fishing days caused by Hurricanes Gustav and Ike, combined with increased energy, labor and repair costs experienced during the 2008 fishing season.

Results for the three and twelve months ended December 31, 2007 were favorably impacted by the settlement of the Company's lawsuit with its property insurance carriers pertaining to damages sustained from Hurricanes Katrina and Rita in 2005. The results for the year ended December 31, 2007 were also impacted by the net loss incurred during the first quarter of 2007 primarily due to the write-off of approximately $3.0 million in deferred debt issuance costs and prepayment fees resulting from the refinancing of the Company's prior credit agreement with a new credit facility which closed in March 2007. Excluding the settlement of the lawsuit and the write-off, reported 2007 net income would have resulted in Omega Protein reporting approximately $7.2 million in net income ($0.43 a share).

About Omega Protein

Omega Protein Corporation is the nation's largest manufacturer of heart-healthy fish oils containing Omega-3 fatty acids for human consumption, as well as specialty fish meals and fish oil used as value-added ingredients in aquaculture, swine and other livestock feeds. Omega Protein makes its products from menhaden, an Omega-3 rich fish that is not utilized as seafood, but which is abundantly available along the U.S. Gulf of Mexico and Atlantic Coasts.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions and disease; (2) the impact of worldwide supply and demand relationships on prices for the Company's products; (3) Omega Protein's expectations regarding demand for OmegaPure(R) proving to be incorrect; (4) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business and its deferral of inventory sales based on worldwide prices for competing products; and (5) the capital and credit market crisis. These and other factors are described in further detail in Omega's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form10-Q and Form 8-K. The Company also posts its latest internally generated price list for various products on its Company website, www.omegaproteininc.com. Pricing and product availability information disclosed in the price list are subject to change or discontinuance without prior notice, and the Company undertakes no obligation to update such information.


                                    OMEGA PROTEIN CORPORATION
                                     Statement of Operations
                                           (unaudited)

                                    Three Months          Twelve Months
                                  Ended December 31,    Ended December 31,
                                   2008       2007       2008        2007
                                  (in thousands, except per share amounts)

    Revenues                     $39,668    $44,336   $177,412     $157,149
    Cost of sales                 31,411     35,650    134,387      122,455
    Gross profit                   8,257      8,686     43,025       34,694
    Selling, general and
     administrative expense        4,436      4,730     16,310       16,386
    Research and
     development expense             477        529      1,757        1,194
    (Insurance recoveries
     and other proceeds)
     losses relating to
     natural disaster and
     other, net                      807     (5,393)     1,415      (10,326)
    Operating income               2,537      8,820     23,543       27,440
    Interest income
     (expense), net                 (903)    (1,111)    (3,779)      (5,121)
    Loss resulting from
     debt refinancing                  -          -          -       (3,024)
    Other income (expense), net      (94)       (87)      (111)        (333)
    Income before income taxes     1,540      7,622     19,653       18,962
    Provision for income taxes       700      2,839      7,077        6,823
    Net income                      $840     $4,783    $12,576      $12,139
    Basic earnings per share       $0.04      $0.27      $0.69        $0.72
    Weighted average common
     shares outstanding           18,710     17,407     18,298       16,830
    Diluted earnings per share     $0.04      $0.27      $0.68        $0.70
    Weighted average common
     shares and potential common
     share outstanding            18,766     17,768     18,581       17,432



                                       OMEGA PROTEIN CORPORATION
                                        CONDENSED BALANCE SHEET
                                              (Unaudited)

                                           December 31,     December 31,
                                               2008             2007
                                     (in thousands, except per share amount)
    ASSETS
      Current assets                          $123,665        $107,651
      Property and equipment, net              106,181          96,659
      Deferred tax assets, net                       -             175
      Other assets                               2,735           3,344
        Total assets                          $232,581        $207,829
    LIABILITIES AND STOCKHOLDERS' EQUITY
      Current liabilities                      $26,853         $24,190
      Long-term debt, less current maturities   51,312          58,976
      Capital lease obligation, net of
       current portion                           1,634               -
      Deferred tax liability,
       net of current portion                    3,005               -
      Pension liabilities, net and other        10,220           6,208
      Stockholders' equity                     139,557         118,455
        Total liabilities and
         stockholders' equity                 $232,581        $207,829

    Book value per share outstanding             $7.46           $6.79


'/>"/>
SOURCE Omega Protein Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Omega-3s Guard Against Type 1 Diabetes
2. Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s
3. Maine Natural Health Company Brings Omega-3 Benefits to Pets
4. Nordic Naturals Introduces Ultimate Omega 500 - Their Best Selling Formula Now Available in a Smaller Size Soft Gel!
5. Omega-3s Linked to Prevention of Parkinsons Disease and More
6. Nordic Naturals Professional Exclusive Division Redefines High Potency Omega-3 Supplementation With New Elite Line!
7. Ongoing Tests Show Kona Kampachi(R) is Rich in Omega-3s With No Detectable Mercury
8. Mayo Clinic proceedings highlights research about cardiovascular benefits of omega-3 fatty acids
9. Omega Protein Reports 2007 Results
10. Infant formula must contain DHA omega-3 and AA omega-6, say international experts
11. Omega-3 Fatty Acids Protect the Spinal Cord, Heart, Brain and Eyes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... ZyDoc , ... Processing–Enabled and Conventional Data Capture Methods for Input to Electronic Health Records: A ... Results of the comparative usability study demonstrate that a dictation-based method (“NLP Entry”) ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, ... recognized for adherence to the highest standards of trauma, maternity, cancer and chronic ... center's president and CEO, Dr. Daniel Messina. , Among the recognitions, the American ...
(Date:12/8/2016)... ... ... Vida Health, the digital health platform that pairs individuals with ... . Other investors include Nokia Growth Partners (NGP) and returning investor Aspect Ventures. Vida ... are managing chronic conditions or simply want to improve their health. Canvas ...
(Date:12/8/2016)... ... ... Coppin Insurance Agency, an insurance and financial planning firm based in Lee ... is embarking on a charity drive with the goal of providing support and donations ... Bank of Southwest Florida works to provide fresh and nutritious food free of charge ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: